Generic Name: osimertinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Tagrisso is a kinase inhibitor approved for people with non-small-cell lung cancer (NSCLC) with certain EGFR mutations.

General Info

Tagrisso interferes with epidermal growth factor receptor (EGFR) proteins that play a role in cancer cell growth and development of blood vessels that feed tumors. Certain EGFR mutations promote lung tumor growth and metastasis.

The FLAURA trial, which enrolled previously untreated people with metastatic NSCLC with specific EGFR mutations, showed that Tagrisso delayed disease progression and improved overall survival more than chemotherapy. The AURA3 study showed that Tagrisso shrank tumors and delayed progression more than chemotherapy in patients who had received prior treatment including other EGFR inhibitors. The ADAURA trial showed that taking Tagrisso after tumor removal reduced the risk of recurrence and improved overall survival. Tagrisso was first approved in 2015.


Dosing Info:

Tagrisso is a once-daily pill that can be taken with or without food.

Side Effects

Common side effects include diarrhea, rash, dry skin, nail problems, fatigue, decreased appetite and low white blood cell and platelet counts. Potential serious side effects may include lung and heart problems and inflammation of the corneas of the eyes. Tagrisso can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: June 5, 2023